¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"mantle zone lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • lymphoblastic lymphoma
    ¸²ÇÁ¸ð±¸¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma staging
    ¸²ÇÁÁ¾º´±â°áÁ¤
  • marginal zone
    °¡ÀåÀÚ¸®±¸¿ª, º¯¿¬´ë
  • neutral zone
    Ç׿øÇ×üÆòÇü±¸¿ª
  • NK/T cell lymphoma
    NK/T¼¼Æ÷¸²ÇÁÁ¾
  • non-Hodgkin¡¯s lymphoma
    ºñÈ£ÁöŲ¸²ÇÁÁ¾
  • ossification zone
    »ÀµÇ±âÃþ, »À¹ß»ýÃþ, °ñÈ­´ë
  • polar zone
    ºÐ±Ø´ë
  • proliferation zone
    Áõ½ÄÃþ
  • reserve zone
    ¿¹ºñÃþ
  • subcutaneous panniculitis-like T-cell lymphoma
    ÇÇÇÏÁö¹æÃþ¿°À¯»çT¼¼Æ÷¸²ÇÁÁ¾
  • subventricular zone
    ³ú½Ç¹Ø±¸¿ª, ³ú½ÇÇÏ´ë
  • well-differentiated lymphocytic lymphoma
    °íºÐÈ­¸²ÇÁ±¸¸²ÇÁÁ¾
  • zone
    1. ±¸¿ª, ¿µ¿ª 2. ´ë 3. Ãþ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • high-zone tolerance
    Ç׿ø°ú·®Çã¿ë
  • inhibition zone
    ¾ïÁ¦¿µ¿ª
  • interface zone
    °æ°è¸é¿µ¿ª
  • internal zone
    ¼ÓÃþ
  • low-zone tolerance
    Ç׿ø¼Ò·®Çã¿ë
  • neutral zone
    Ç׿øÇ×üÆòÇü±¸¿ª
  • odontogenic zone
    Ä¡¾Æ¹ß»ýÃþ, Á¶Ä¡Ãþ
  • ossification zone
    »À¹ß»ýÃþ
  • polar zone
    ºÐ±Ø´ë
  • proliferation zone
    Áõ½ÄÃþ
  • radiolucent zone
    ¹æ»ç¼±Åõ°ú¿µ¿ª
  • reserve zone
    ¿¹ºñÃþ
  • root entry zone
    ½Å°æ»Ñ¸®ÁøÀÔºÎ
  • sclerotic zone
    °ø¸·´ë
  • temperate zone strain
    ¿Â´ëÁö¿ªÁÖ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • heating zone
    °¡¿­´ë(Ê¥æðÓá).
  • high-zone tolerance
    °í¿ª°ü¿ë, Ç׿ø°ú·®°ü¿ë
  • hypertrophic zone
    ºñ´ëÃþ
  • hypnogenous zone
    ÃÖ¸é´ë(õÊØùÓá)
  • infective zone
    °¨¿°´ë(˧ËçËÀ), Àü¿°´ë (ËøËçËÀ).
  • inhibition zone
    ¾ïÁ¦´ë(åäð¤Óá).
  • inhibitory zone
    ¾ïÁ¦¹üÀ§(åäð¤ÛôêÌ).
  • inner zone
    ³»´ë(Ò®Óá).
  • polar zone
    ºÐ±Ø´ë.
  • proliferation zone
    Áõ½ÄÃþ
  • pupillary area =p. zone
    µ¿°ø¾ß(ÔÚÍîå¯).
  • pupillary zone
    µ¿°ø¿µ¿ª, µ¿°ø´ë(ÔÚÍîÓá), µ¿°ø¾ß.
  • pupillary zone
    µ¿°øºÎÀ§(ÔÚÍîÓá)
  • radiolucent zone
    ¹æ»ç¼± Åõ°ú ¿µ¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • large cell anaplastic lymphoma
    ´ë¼¼Æ÷ ÅðÇ༺ ¸²ÇÁÁ¾
  • large cell lymphoma
    ´ë¼¼Æ÷ ¸²ÇÁÁ¾
  • leukemia/lymphoma
    ¹éÇ÷º´/¸²ÇÁÁ¾(ÛÜúìÜ»/¡­ðþ)
  • lymphoepithelioid lymphoma
    ¸²ÇÁÇ¥ÇÇ¾ç ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾
  • lymphoma
    ¸²ÇÁÁ¾.
  • lymphoma
    ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma cells
    ¸²ÇÁÁ¾¼¼Æ÷(¡­á¬øà)
  • lymphoma, Burkitts
    ¹öŶƮ ¸²ÇÁÁ¾
  • lymphoma,burkitts
    ¹öŶ¸²ÇÁÁ¾, Burkitt ¸²ÇÁÁ¾(¡­ðþ)
  • lymphoma,follicular
    ¿©Æ÷¼º¸²ÇÁÁ¾(æ¤øààõ¡­ðþ)
  • lymphoma,large cell, diffuse
    ´ë¼¼Æ÷¼º ¸²ÇÁÁ¾(ÓÞá¬øààõ ¡­ðþ)
  • lymphoma,lymphoblastic
    ¸²ÇÁ¸ð±¸¼º ¸²ÇÁÁ¾(¡­Ù½Ï¹àõ ¡­)
  • lymphoma,lymphocytic
    ¸²ÇÁ±¸¼º(¡­Ï¹àõ)
  • lymphoma,mucosa-associated lymphoid tissue
    Á¡¸·°ü·Ã ¸²ÇÁÁ¶Á÷(ïÄØ¯Î¼Ö¤ ¡­ðÚòÄ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
A [band] the dark-staining zone of a striated muscle
ATZ atypical transformation zone
AVZ avascular zone
BMZ basement membrane zone
CDZ chlordiazepoxide; conduction delay zone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DREZ Dorsal Root Entry Zone
LLETZ Large Loop Excision of the Transformation Zone
MZ Marginal zone
NZ Neutral zone
PZ Peripheral zone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • infective zone
    °¨¿°´ë, Àü¿°´ë
    °¨¿°ÀÇ À§Ç輺ÀÌ ÀÖ´Â ºÎÀ§.
  • inhibition zone
    ¾ïÁ¦´ë
    ħ°­ ¶Ç´Â ÀÀÁý ¹ÝÀÀ¿¡¼­ Ç×ü ³óµµ°¡ ³ôÀº Ç÷û¿¡¼­´Â Ç׿ø ÀÔÀÚ¿Í ¹ÝÀÀÀ» ³ªÅ¸³»Áö ¾Ê´Â Çö»ó.
  • intermediate zone
    Áß°£´ë, Áß¾ÓºÎ, °üÀý ¿øÆÇ Áß°£ºÎ
  • junctional zone
    Á¢ÇÕ ºÎÀ§
  • latent zone
    Àẹ´ë
    ¼¼±ÕÀÇ ÀÏ»ý¿¡¼­ Àẹ±â
  • Looser's zone
    Looser Áö¿ª, Looser ´ë
  • motor zone
    ¿îµ¿´ë
  • nominal hazard zone
    ÁöÁ¤µÈ À§ÇØ Áö¿ª
  • odontogenic zone
    Á¶Ä¡Ãþ
  • opaque zone
    ºÒÅõ¸í Ãþ
  • pale(o) °í ¶Ç´Â ±¸¸¦ ¶æÇÏ´Â Á¢µÎ¾î.

    pale-staining zone

    ¿¯Àº ¿°»öÃþ
  • paracortial zone
    °çÇÇÁú °¡½¿»ù ÀÇÁ¸´ë, Èä¼± ÀÇÁ¸´ë
  • proliferative zone
    Áõ½Ä´ë
  • radiolucent zone
    ¹æ»ç¼± Åõ°ú ¿µ¿ª
  • referral zone
    ÀüÀÌ Áö¿ª
    µ¿ÀǾî=reference zone. ÀüÀÌ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
T-cell lymphoma A cancer of the immune system that appears in the skin; also called mycosis fungoides.
(12 Dec 1998)
T-cell-rich, B-cell lymphoma <tumour> A B-cell lymphoma in which more than 90% of the cells are of T-cell origin, masking the large cells that form the neoplastic B-cell component.
See: adult T-cell lymphoma.
(05 Mar 2000)
extra nodal lymphoma <oncology, tumour> Literally outside the lymph nodes, but exhibiting the characteristics of lymph node cancer. A term used to describe the extent and site of disease.
(27 Sep 1997)
Ki-1+ lymphoma <tumour> A form of lymphoma characterised by anaplasia of cells, sinusoidal growth, and immunoreactivity with CD30 (Ki-1 or Ber-H2).
Synonym: Ki-1+ lymphoma.
(05 Mar 2000)
follicular lymphoma <tumour> A malignant lymphoma arising from lymphoid follicular B-cells which may be small or large, growing in a nodular pattern.
Synonym: follicular lymphoma, giant follicular lymphoblastoma.
(05 Mar 2000)
follicular predominantly large cell lymphoma <tumour> A B-cell lymphoma of intermediate malignancy.
(05 Mar 2000)
follicular predominantly small cleaved cell lymphoma <tumour> A B-cell lymphoma with nodular or diffuse lymph node or bone marrow involvement by large lymphoid cells.
Synonym: follicular predominantly small cleaved cell lymphoma, nodular histiocytic lymphoma.
(05 Mar 2000)
large cell lymphoma <oncology, tumour> Highly malignant group of tumours arising from transformed lymphocytes or myeloid precursors. Cell of origin often obscure.
(18 Nov 1997)
Lennert's lymphoma <tumour> Malignant lymphoma with a high proportion of diffusely scattered epithelioid cells, tonsillar involvement, and an unpredictable course.
Synonym: Lennert's lesion.
(05 Mar 2000)
lymphoblastic lymphoma <tumour> A diffuse lymphoma in children, with supradiaphragmatic distribution and T lymphocytes having convoluted nuclei; many patients develop acute lymphoblastic leukaemia.
(05 Mar 2000)
lymphocytic lymphoma <oncology, tumour> A cancer of lymphatic tissues, the tumour cells are mostly abnormal lymphocytes.
(13 Nov 1997)
lymphoma <oncology, tumour> Malignant tumour of lymphoblasts derived from B lymphocytes. most commonly affects children in tropical Africa: both Epstein Barr virus and immunosuppression due to malarial infection are involved.
(18 Nov 1997)
lymphoma, aids-related B-cell lymphoid tumours that occur in association with aids. Patients often present with an advanced stage of disease and highly malignant subtypes including burkitt lymphoma, immunoblastic large-cell lymphoma, small non-cleaved-cell lymphoma and diffuse large-cell lymphoma. The tumours are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in aids is a complex result of ebv infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
(12 Dec 1998)
lymphoma, B-cell A group of heterogeneous lymphoid tumours generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
(12 Dec 1998)
lymphoma, diffuse Malignant lymphoma in which neoplastic cells diffusely infiltrate the entire lymph node without any definite organised pattern. Patients whose lymphomas present a diffuse pattern generally have a more unfavorable survival outlook than those presenting with a follicular or nodular pattern.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • safety zone
    ¾ÈÀüÁö´ë
  • takeover zone
    (À°»óÀÇ ¸±·¹ÀÌ¿¡¼­) ¹ÙÅæÀ» ÁÖ°í ¹Þ´Â ±¸¿ª
  • towaway zone
    ÁÖÂ÷±ÝÁö Áö´ë(À§¹Ý Â÷·®Àº ²ø¾î°¨)
  • twilight zone
    Áß°£ Áö´ë;°æ°è ¿µ¿ª;µµ½ÃÀÇ ³ëÈÄÈ­ Áö¿ª
  • zone
    ´ë;Áö´ë;±¸¿ª;µ¿ÀÏ ¿ä±Ý ±¸¿ª
  • zone defense
    Áö¿ª ¹æ¾î
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á